Experimental genital herpes vaccine fails major clinical trial

An experimental vaccine designed to block genital transmission of herpes viruses from men to women has failed a major clinical trial aimed at obtaining manufacturing approval, researchers said Thursday. Because of the failure, the vaccine's manufacturer, GlaxoSmithKline, said it will abandon any further attempts to develop the vaccine, called Simplirix.